Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Sun, Yu Yo ^a   Morozov, Yury M ^b   Yang, Dianer ^a   Li, Yikun ^a   Dunn, R Scott ^c   Rakic, Pasko ^b   Chan, Pak H ^d   Abe, Koji ^e   Lindquist, Diana M ^c   Kuan, Chia Yi ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MATRIX METALLOPROTEINASE; NORPHENAZONE; OXYGEN; TISSUE PLASMINOGEN ACTIVATOR; PHENAZONE; PHENYLMETHYLPYRAZOLONE;

ADULT; ANIMAL EXPERIMENT; ARTICLE; BRAIN BLOOD FLOW; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMMON CAROTID ARTERY; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; DRUG POTENTIATION; ENZYME ACTIVITY; EXPERIMENTAL THROMBOTIC STROKE; MALE; MORTALITY; MOUSE; NONHUMAN; OXIDATIVE STRESS; REPERFUSION; THROMBOSIS; WHITE MATTER; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CELL HYPOXIA; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; INJURIES; METABOLISM; OCCLUSIVE CEREBROVASCULAR DISEASE; PATHOPHYSIOLOGY; STROKE;

ANIMALS; ANTIPYRINE; CELL HYPOXIA; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; HUMANS; HYPOXIA-ISCHEMIA, BRAIN; INTRACRANIAL THROMBOSIS; MALE; MICE; MICE, INBRED C57BL; STROKE; TISSUE PLASMINOGEN ACTIVATOR; WHITE MATTER;

EID: 84902668917     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098807     Document Type: Article

References (43)

1. Khatri P, Neff J, Broderick JP, Khoury JC, Carrozzella J, et al. (2005) Revascularization end points in stroke interventional trials: recanalization versus reperfusion in IMS-I. Stroke 36: 2400-2403. (Pubitemid 41566966)
2. De Silva DA, Fink JN, Christensen S, Ebinger M, Bladin C, et al. (2009) Assessing reperfusion and recanalization as markers of clinical outcomes after intravenous thrombolysis in the echoplanar imaging thrombolytic evaluation trial (EPITHET). Stroke 40: 2872-2874.
3. del Zoppo GJ, Mabuchi T (2003) Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab 23: 879-894.
4. Barreto AD, Alexandrov AV (2012) Adjunctive and alternative approaches to current reperfusion therapy. Stroke 43: 591-598.
5. Amaro S, Chamorro A (2011) Translational stroke research of the combination of thrombolysis and antioxidant therapy. Stroke 42: 1495-1499.
6. Hossmann KA (2012) The two pathophysiologies of focal brain ischemia: implications for translational stroke research. J Cereb Blood Flow Metab 32: 1310-1316.
7. Orset C, Macrez R, Young AR, Panthou D, Angles-Cano E, et al. (2007) Mouse model of in situ thromboembolic stroke and reperfusion. Stroke 38: 2771-2778. (Pubitemid 47494017)
8. Niessen F, Hilger T, Hoehn M, Hossmann KA (2003) Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke. Stroke 34: 2019-2024. (Pubitemid 36944800)
9. Adhami F, Liao G, Morozov YM, Schloemer A, Schmithorst VJ, et al. (2006) Cerebral ischemia-hypoxia induces intravascular coagulation and autophagy. Am J Pathol 169: 566-583. (Pubitemid 44156315)
10. Lapchak PA (2010) A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother 11: 1753-1763.
11. Yagi K, Kitazato KT, Uno M, Tada Y, Kinouchi T, et al. (2009) Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. Stroke 40: 626-631.
12. Yamashita T, Kamiya T, Deguchi K, Inaba T, Zhang H, et al. (2009) Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb Blood Flow Metab 29: 715-725.
13. Lapchak PA, Zivin JA (2009) The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator. Exp Neurol 215: 95-100.
14. Shereen A, Nemkul N, Yang D, Adhami F, Dunn RS, et al. (2011) Ex vivo diffusion tensor imaging and neuropathological correlation in a murine model of hypoxia-ischemia-induced thrombotic stroke. J Cereb Blood Flow Metab 31: 1155-1169.
15. Yang D, Nemkul N, Shereen A, Jone A, Dunn RS, et al. (2009) Therapeutic administration of plasminogen activator inhibitor-1 prevents hypoxic-ischemic brain injury in newborns. J Neurosci 29: 8669-8674.
16. Sun YY, Yang D, Kuan CY (2012) Mannitol-facilitated perfusion staining with 2,3,5-triphenyltetrazolium chloride (TTC) for detection of experimental cerebral infarction and biochemical analysis. J Neurosci Methods 203: 122-129.
17. Briers JD (2001) Laser Doppler, speckle and related techniques for blood perfusion mapping and imaging. Physiol Meas 22: R35-66.
18. Yang D, Sun YY, Nemkul N, Baumann JM, Shereen A, et al. (2013) Plasminogen Activator Inhibitor-1 Mitigates Brain Injury in a Rat Model of Infection-Sensitized Neonatal Hypoxia-Ischemia. Cereb Cortex 23: 1218-1229.
19. Li PA, Vogel J, Smith M, He QP, Kuschinsky W, et al. (1998) Capillary patency after transient middle cerebral artery occlusion of 2 h duration. Neurosci Lett 253: 191-194. (Pubitemid 28442595)
20. Sun YY, Wang CY, Hsu MF, Juan SH, Chang CY, et al. (2010) Glucocorticoid protection of oligodendrocytes against excitotoxin involving hypoxia-inducible factor-1alpha in a cell-type-specific manner. J Neurosci 30: 9621-9630.
21. Murakami K, Kondo T, Kawase M, Li Y, Sato S, et al. (1998) Mitochondrial susceptibility to oxidative stress exacerbates cerebral infarction that follows permanent focal cerebral ischemia in mutant mice with manganese superoxide dismutase deficiency. J Neurosci 18: 205-213. (Pubitemid 28046782)
22. Sashindranath M, Samson AL, Downes CE, Crack PJ, Lawrence AJ, et al. (2011) Compartment- and context-specific changes in tissue-type plasminogen activator (tPA) activity following brain injury and pharmacological stimulation. Lab Invest 91: 1079-1091.
23. Kimura K, Aoki J, Sakamoto Y, Kobayashi K, Sakai K, et al. (2012) Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients - a preliminary study. J Neurol Sci 313: 132-136.
24. Lee BJ, Egi Y, van Leyen K, Lo EH, Arai K (2010) Edaravone, a free radical scavenger, protects components of the neurovascular unit against oxidative stress in vitro. Brain Res 1307: 22-27.
25. Romanos E, Planas AM, Amaro S, Chamorro A (2007) Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab 27: 14-20. (Pubitemid 46006580)
26. Garcia-Yebenes I, Sobrado M, Zarruk JG, Castellanos M, Perez de la Ossa N, et al. (2010) A mouse model of hemorrhagic transformation by delayed tissue plasminogen activator administration after in situ thromboembolic stroke. Stroke 42: 196-203.
27. Abe K, Yuki S, Kogure K (1988) Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke 19: 480-485.
28. Watanabe T, Yuki S, Egawa M, Nishi H (1994) Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther 268: 1597-1604. (Pubitemid 24100383)
29. Edaravone Acute Infarction Study Group (2003) Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 15: 222-229.
30. Matute C, Domercq M, Perez-Samartin A, Ransom BR (2013) Protecting white matter from stroke injury. Stroke 44: 1204-1211.
31. Margaill I, Plotkine M, Lerouet D (2005) Antioxidant strategies in the treatment of stroke. Free Radic Biol Med 39: 429-443. (Pubitemid 41021642)
32. Martin A, Boisgard R, Theze B, Van Camp N, Kuhnast B, et al. (2010) Evaluation of the PBR/TSPO radioligand [(18)F]DPA-714 in a rat model of focal cerebral ischemia. J Cereb Blood Flow Metab 30: 230-241.
33. Dalkara T, Arsava EM (2012) Can restoring incomplete microcirculatory reperfusion improve stroke outcome after thrombolysis? J Cereb Blood Flow Metab 32: 2091-2099.
34. Macrae IM (2011) Preclinical stroke research - advantages and disadvantages of the most common rodent models of focal ischaemia. Br J Pharmacol 164: 1062-1078.
35. Heiss WD (2011) The ischemic penumbra: correlates in imaging and implications for treatment of ischemic stroke. The Johann Jacob Wepfer award 2011. Cerebrovasc Dis 32: 307-320.
36. Kaste M, Murayama S, Ford GA, Dippel DW, Walters MR, et al. (2013) Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen. Cerebrovasc Dis 36: 196-204.
37. Watanabe T, Tahara M, Todo S (2008) The novel antioxidant edaravone: from bench to bedside. Cardiovasc Ther 26: 101-114. (Pubitemid 351952827)
38. Zhang N, Komine-Kobayashi M, Tanaka R, Liu M, Mizuno Y, et al. (2005) Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 36: 2220-2225. (Pubitemid 41429250)
39. Korninger C, Collen D (1981) Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost 46: 561-565. (Pubitemid 11049531)
40. Haelewyn B, Risso JJ, Abraini JH (2010) Human recombinant tissue-plasminogen activator (alteplase): why not use the 'human' dose for stroke studies in rats? J Cereb Blood Flow Metab 30: 900-903.
41. Zhang W, Sato K, Hayashi T, Omori N, Nagano I, et al. (2004) Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain. Neurol Res 26: 342-348. (Pubitemid 38620058)
42. Yamauchi H, Higashi T, Kagawa S, Nishii R, Kudo T, et al. (2012) Is misery perfusion still a predictor of stroke in symptomatic major cerebral artery disease? Brain 135: 2515-2526.
43. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, et al. (2009) Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40: 2244-2250.